Searched for
UTI
Only 1/5th the size of NSE? Why Jefferies predicts 27% upside for this near-monopoly stockJefferies has initiated coverage on MCX with a Buy rating and a target price of Rs 3,600, implying 27% upside. The brokerage expects strong...- UTI Mutual Fund buys nearly 15 lakh shares of MCX for Rs 425 croreUTI Mutual Fund has significantly boosted its stake in MCX, acquiring nearly 15 lakh shares for a substantial Rs 425 crore via an open mark...
- Looking for low cost and high return funds in 3 months? Kotak Liquid Fund among top 5These low-cost liquid and overnight mutual funds combined minimal expense ratios with competitive three-month returns. PGIM India Liquid Fu...
- Woman says she was threatened to resign just 15 days into her first corporate job. 'The trauma lasted a year'A young woman's Reddit post alleging that she was fired from her first corporate job after just 15 days has gone viral, sparking conversati...
- Largecaps over midcaps, banks over PSUs: V Srivatsa reveals where smart money is headingIndia's market outlook is positive, driven by cooling geopolitical tensions and falling crude oil prices, according to UTI AMC's V Srivatsa...
- These 5 flexicap mutual funds delivered single-digit returns in 3 years. Check details
- Societe General, Prudential, others buy 3 per cent stake in Anthem Biosciences for Rs 1,275 crGlobal investors including Societe Generale and Prudential Hong Kong, alongside Indian mutual funds and insurance companies, have bought a ...
- Best flexi cap mutual funds to invest in June 2026Flexi cap mutual funds provide a flexible investment avenue for investors navigating market volatility. Fund managers can strategically all...
- Planning a SIP this June? Here are mutual fund options that could suit aggressive investorsAggressive investors planning SIPs in June can consider a mix of flexi-cap, large-cap, mid-cap, small-cap and hybrid funds across investmen...
- Edelweiss Alternatives’ Subahoo Chordia quits, likely to launch own fundSubahoo Chordia, a key figure at Edelweiss Alternatives, has departed to launch his own infrastructure fund. He was instrumental in buildin...
- Gold and silver ETFs slip up to 8% amid Israel attack and crude oil spike. What should investors do?Gold and silver ETFs declined sharply on Monday as precious metal prices corrected on the MCX amid rising crude oil prices, inflation conce...
- 8 smallcap funds struggled with consistency in the last 5 years. Do you own any?Eight smallcap mutual funds showed low five-year performance consistency, according to CRISP Scorecard, with varied risk profiles, investme...
- Every mutual fund offers positive XIRR on SIP investments in 5 years. Did you exit too soon?Equity mutual funds delivered positive returns on Systematic Investment Plans over the past five years. Many funds provided double-digit XI...
- Wockhardt shares pause massive 36% rally in 5 sessions; slip 7%. What’s behind the selloff?Wockhardt shares dropped after a recent surge, as investors took profits. This followed the US FDA approval of ZAYNICH, an antibiotic for u...
- Crude oil shock clouds near-term outlook, but FY27 earnings growth still intact: Karthikraj LakshmananUTI AMC's Karthikraj Lakshmanan sees cautiously optimistic Indian market outlook with intact FY27 earnings trajectory, despite near-term cr...
- Wockhardt shares rocket 19% after FDA approval for antibiotic targeting drug-resistant infections. Check detailsWockhardt's shares surged 19% after the U.S. FDA approved ZAYNICH, a novel intravenous antibiotic for complicated urinary tract infections....
- FDA approval puts Wockhardt’s Zaynich in $9 billion antibiotics marketWockhardt's new antibiotic, Zaynich, has received US FDA approval. This drug uses a novel mechanism to fight drug-resistant bacteria. It ta...
- 20 months of bearish markets: One additional letter that tells you which 'cheap' stocks are actually cheapMost investors live by one ratio. That ratio that tells them all they want to know – or should one say all they want to hear? They open a s...
- Wockhardt secures US FDA approval for antibiotic ZaynichWockhardt's novel antibiotic, Zaynich (cefepime and zidebactam), has received US FDA approval for complicated urinary tract infections. Thi...
- Wockhardt gets CDSCO nod for Zaynich antibioticWockhardt Ltd has secured approval from the CDSCO for its new antibiotic, Zaynich. This drug is developed in India and will be used to trea...
Load More
